The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Improving treatment access by extending clinical trials to local hospitals in the UK
Sunil Gupta, MD, FRCP, FRCPath, MBA, Lewisham and Greenwich NHS Trust, London, UK, discusses the importance of expanding clinical trials beyond teaching hospitals to district general hospitals in the UK, where they can benefit a broader patient population. Dr Gupta highlights the success of clinical trials in his own trust, and emphasizes the need for more research-active clinicians and increased access to clinical trials. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Clinical trials in the UK are again more concentrated towards the teaching hospitals, which I think is not the correct way of putting clinical trials to the general public and to the patients. So, more and more clinical trials, the drug companies should come to the district general hospital also, where these clinical trials can be run. I’m the clinical trial lead for our trust and we have got trials, a few trials, but not as many as we could have actually managed and we could have actually started to benefit the patients...
Clinical trials in the UK are again more concentrated towards the teaching hospitals, which I think is not the correct way of putting clinical trials to the general public and to the patients. So, more and more clinical trials, the drug companies should come to the district general hospital also, where these clinical trials can be run. I’m the clinical trial lead for our trust and we have got trials, a few trials, but not as many as we could have actually managed and we could have actually started to benefit the patients. So, we need to be offered more clinical trials. We have got a very good and large, robust, very efficient team from the nursing point of view, and at the same time, we have got a large clinical team to look after the clinical trial. I know the clinical trial is a massive amount of work, we have to be very cautious, and we have to have frequent visits of the patients, and we need to examine these patients very frequently, but we are fully prepared for that. And I would like to mention that I have got a 93-year-old gentleman who has multiple myeloma, and three years down the line, he’s been very, very well on a clinical trial, he’s on a fitness trial, and you wouldn’t imagine that he comes to the clinic without a stick, without any help, and his outcome has improved massively. At the age of 92, you can imagine, at this age, people start thinking, “Oh, why do we need to actually treat?” Leave aside the clinical trial, but this patient has massively improved. And we have another patient who had AML, he’s 65, he was on the VICTOR trial for AML for the NPM1 positive patient, and three years down the line, this patient, without the need of transplantation, only with chemotherapy, now he’s actually doing a world tour, he’s doing cruises, he’s fit as a fiddle at the moment, and he can’t believe that his life has changed so much in the last three years, just because of the clinical trial. So, I would make my center even more research-centric and invite more patients, and also, at the same time, ask my colleagues to encourage them to become more research-active in the center.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
